Skip to Content

New Drug Approvals Archive - April 2013

April 2013

Prolensa (bromfenac) Ophthalmic Solution

Date of Approval: April 5, 2013
Company: Bausch + Lomb
Treatment for: Postoperative Ocular Inflammation

Prolensa (bromfenac ophthalmic solution) is a topical nonsteroidal anti-inflammatory indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Diclegis (doxylamine and pyridoxine) Delayed-Release Tablets

Date of Approval: April 8, 2013
Company: Duchesnay Inc.
Treatment for: Nausea and Vomiting of Pregnancy

Diclegis (doxylamine and pyridoxine) is an antihistamine and vitamin B6 analog combination indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

Topicort (desoximetasone)

New Formulation Approved: April 11, 2013

Sitavig (acyclovir) Buccal Tablets

Date of Approval: April 12, 2013
Company: BioAlliance Pharma SA
Treatment for: Herpes Simplex Labialis

Sitavig (acyclovir) is a mucoadhesive buccal tablet formulation of the antiviral drug acyclovir indicated for the treatment of recurrent orofacial herpes (cold sores).

Simbrinza (brimonidine and brinzolamide) Ophthalmic Suspension

Date of Approval: April 19, 2013
Company: Alcon
Treatment for: Glaucoma

Simbrinza (brimonidine and brinzolamide) is a fixed combination of an alpha 2 adrenergic receptor agonist and a carbonic anhydrase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Amitiza (lubiprostone)

New Indication Approved: April 19, 2013
Treatment for: Chronic Idiopathic Constipation, Opioid-Induced Constipation, Irritable Bowel Syndrome with Constipation

Kcentra (prothrombin complex concentrate, human)

Date of Approval: April 29, 2013
Company: CSL Behring
Treatment for: Reversal of Vitamin K Antagonist (VKA) Anticoagulation

Procysbi (cysteamine bitartrate) Delayed-Release Capsules

Date of Approval: April 30, 2013
Company: Raptor Pharmaceutical Corp.
Treatment for: Nephropathic Cystinosis

Procysbi (cysteamine bitartrate) is a cystine depleting agent indicated for the treatment of nephropathic cystinosis.

Procysbi (cysteamine bitartrate)

Patient Population Altered: August 14, 2015
Treatment for: Nephropathic Cystinosis

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.